- Conditions
- Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
- Interventions
- [F-18]-5-FLUORO-2'-DEOXYCYTIDINE, Tetrahydrouridine intravenous (IV), Tetrahydrouridine (oral), Positron emission tomography (PET)/Computed tomography (CT)
- Drug · Diagnostic Test
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 144
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Non-Melanoma Skin Cancer
- Interventions
- UV Counseling
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma, Non-prostate Extrapulmonary Neuroendocrine Carcinoma, Cervical Neuroendocrine Carcinoma, Thymic Neuroendocrine Carcinoma, Genitourinary Neuroendocrine Carcinoma, Unknown Primary Neuroendocrine Carcinomas, Merkel Cell Carcinoma, Medullary Thyroid Carcinoma
- Interventions
- 225Ac-ETN029, 111In-ETN029
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 4
- States / cities
- Iowa City, Iowa • Boston, Massachusetts • Royal Oak, Michigan + 1 more
- Conditions
- Prostate Cancer
- Interventions
- 11C-sarcosine, 11C-choline
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 40 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- 3'-Deoxy-3'-[18F]-fluorothymidine, Chemical-shift-encoded MRI
- Drug · Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Diagnostic Imaging
- Interventions
- BAY1075553
- Drug
- Lead sponsor
- Lantheus Biosciences Ltd.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Hepatocellular Carcinoma
- Interventions
- TheraSphere
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 6
- States / cities
- Stanford, California • Gainesville, Florida • Chicago, Illinois + 3 more
- Conditions
- Neuroendocrine Tumors
- Interventions
- Satoreotide tetraxetan, Amino acid solution, Antiemetic
- Drug · Other
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- F-Var3 PET/CT, Blood draw
- Diagnostic Test · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Locally Confined Adenocarcinoma of the Prostate
- Interventions
- Image Guided Dynamic Dosimetry
- Device
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
- Interventions
- Computed Tomography, Hepatobiliary Iminodiacetic Acid Scan, Single Photon Emission Computed Tomography, Yttrium Y 90 Glass Microspheres, Yttrium-90 Microsphere Radioembolization
- Procedure · Other · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Dosimetry, Pharmacokinetics
- Interventions
- [11C]LY2428703
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cancer
- Interventions
- [18F]F-AraG
- Drug
- Lead sponsor
- CellSight Technologies, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Thyroid Cancer, RAI-Refractory Thyroid Cancer
- Interventions
- Disease status detection, Theranostic dosimetry, I-124 PET/CT imaging
- Diagnostic Test · Drug
- Lead sponsor
- Miami Cancer Research Center, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- North Miami, Florida
- Conditions
- Bone Pain, Metastatic Bone Tumor, Bone Metastases in Subjects With Advanced Cancer
- Interventions
- 153Sm-DOTMP
- Drug
- Lead sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- Miami, Florida • Houston, Texas
- Conditions
- Malignant Central Nervous System Neoplasm, Malignant Skull Base Neoplasm
- Interventions
- Medical Chart Review
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Hepatocellular Carcinoma
- Interventions
- CT Liver Perfusion, PET/CT of liver
- Radiation
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Neuroendocrine Tumors
- Interventions
- 177Lu-DOTA-EB-TATE, Amino Acid Solution
- Drug · Other
- Lead sponsor
- Molecular Targeting Technologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Systemic Amyloidosis
- Interventions
- 99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m., 99mTc-Pyrophosphate
- Drug
- Lead sponsor
- University of Tennessee Graduate School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- AAA617, Gonadotropin-releasing hormone (GnRH) analogues, Gonadotropin-releasing hormone (GnRH) antagonists
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Palo Alto, California • Rochester, Minnesota + 2 more
- Conditions
- Inoperable Solid Tumors or Lymphomas
- Interventions
- AvidinOX, 177Lu-ST2210
- Drug
- Lead sponsor
- Alfasigma S.p.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hepatocellular Carcinoma (HCC), Solid Tumors
- Interventions
- BAY3630942, BAY3547922
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 1 more
- Conditions
- Neuroendocrine Tumors, Somatostatin Receptor-positive Neuroendocrine Tumor
- Interventions
- Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT), Photon Emission Tomography / CT (PET/CT), 64Cu-Dotatate, 177Lu-Dotatate
- Device · Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Coronary Artery Disease
- Interventions
- CardioPET
- Drug
- Lead sponsor
- Fluoropharma, Inc.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts